TY - JOUR
T1 - Risk of psychiatric disorders in patients with chronic insomnia and sedative-hypnotic prescription
T2 - A nationwide population-based follow-up study
AU - Chung, Kuo Hsuan
AU - Li, Chung Yi
AU - Kuo, Shu Yu
AU - Sithole, Trevor
AU - Liu, Wen Wei
AU - Chung, Min Huey
PY - 2015
Y1 - 2015
N2 - Study Objectives: Previous epidemiological studies have established insomnia as a major risk factor for mood, anxiety, and substance use disorders. However, the associations between insomnia with sedative-hypnotic prescriptions and various psychiatric disorders have not been thoroughly examined. The current study involved evaluating the risk of psychiatric disorders, namely schizophrenia, mood, anxiety, somatoform, and substance-related disorders, over a 6-y follow-up period in three groups: patients with insomnia and sedative-hypnotic prescriptions (Inso-Hyp), those with insomnia and without sedative-hypnotic prescriptions (Inso- NonHyp), and those with neither insomnia nor sedativehypnotic prescriptions (NonInso-NonHyp). Methods: We used a historical cohort study design to compare the risk of psychiatric disorders among the three groups. Data regarding these patients were derived from reimbursement claims recorded in Taiwan's National Health Insurance Research Database. Cox proportional hazards regression was used to compare the 6-y risk of subsequent psychiatric disorders among the Inso-Hyp, Inso-NonHyp, and NonInso-NonHyp groups. Results: Compared with the Inso-NonHyp and NonInso- NonHyp group patients, the Inso-Hyp group patients exhibited a higher risk of psychiatric disorders, particularly bipolar disorders (adjusted hazard ratio [AHR]: 7.60; 95% confi dence interval [CI]: 5.31-10.89 and AHR: 14.69; 95% CI: 11.11-19.43, respectively). Moreover, among the Inso-Hyp patient group, insomnia prescribed with benzodiazepine, a longer duration of sedative-hypnotic action, and higher doses of sedativehypnotics were signifi cantly associated with a higher risk of depressive and anxiety disorders. Conclusion: The Inso-Hyp group exhibited a higher risk of developing psychiatric disorders than did the Inso-NonHyp and NonInso-NonHyp groups. The results regarding patients with insomnia and sedative-hypnotic prescriptions associated with the risk of psychiatric disorders can serve as a reference for care providers when managing sleep disturbances.
AB - Study Objectives: Previous epidemiological studies have established insomnia as a major risk factor for mood, anxiety, and substance use disorders. However, the associations between insomnia with sedative-hypnotic prescriptions and various psychiatric disorders have not been thoroughly examined. The current study involved evaluating the risk of psychiatric disorders, namely schizophrenia, mood, anxiety, somatoform, and substance-related disorders, over a 6-y follow-up period in three groups: patients with insomnia and sedative-hypnotic prescriptions (Inso-Hyp), those with insomnia and without sedative-hypnotic prescriptions (Inso- NonHyp), and those with neither insomnia nor sedativehypnotic prescriptions (NonInso-NonHyp). Methods: We used a historical cohort study design to compare the risk of psychiatric disorders among the three groups. Data regarding these patients were derived from reimbursement claims recorded in Taiwan's National Health Insurance Research Database. Cox proportional hazards regression was used to compare the 6-y risk of subsequent psychiatric disorders among the Inso-Hyp, Inso-NonHyp, and NonInso-NonHyp groups. Results: Compared with the Inso-NonHyp and NonInso- NonHyp group patients, the Inso-Hyp group patients exhibited a higher risk of psychiatric disorders, particularly bipolar disorders (adjusted hazard ratio [AHR]: 7.60; 95% confi dence interval [CI]: 5.31-10.89 and AHR: 14.69; 95% CI: 11.11-19.43, respectively). Moreover, among the Inso-Hyp patient group, insomnia prescribed with benzodiazepine, a longer duration of sedative-hypnotic action, and higher doses of sedativehypnotics were signifi cantly associated with a higher risk of depressive and anxiety disorders. Conclusion: The Inso-Hyp group exhibited a higher risk of developing psychiatric disorders than did the Inso-NonHyp and NonInso-NonHyp groups. The results regarding patients with insomnia and sedative-hypnotic prescriptions associated with the risk of psychiatric disorders can serve as a reference for care providers when managing sleep disturbances.
KW - Anxiety disorder
KW - Bipolar disorder
KW - Depressive disorder
KW - Insomnia
KW - Schizophrenia
KW - Sedative-hypnotics
KW - Somatoform disorder
KW - Substance-related disorder
UR - http://www.scopus.com/inward/record.url?scp=84929312290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929312290&partnerID=8YFLogxK
U2 - 10.5664/jcsm.4700
DO - 10.5664/jcsm.4700
M3 - Article
C2 - 25766696
AN - SCOPUS:84929312290
SN - 1550-9389
VL - 11
SP - 543
EP - 551
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 5
ER -